Comparison of curative effects of intravitreal injection of Ranibizumab and Conbercept in the treatment of diabetic macular edema

• Main Authors: Yang Guo, Li-Ting Hou, Hong-Xia Hu, Yan-Zhu Ren
• Format: Article
• Language: English
• Published: Press of International Journal of Ophthalmology (IJO PRESS) 2018-01-01
• Series: Guoji Yanke Zazhi
• Subjects: diabetic macular edema; intravitreal injection; ranibizumab; conbercept
• Online Access: http://ies.ijo.cn/cn_publish/2018/1/201801013.pdf

AIM: To comparatively analyze curative effects of intravitreal injection of Ranibizumab and Conbercept in the treatment of diabetic macular edema. <p>METHODS: Retrospectively analyzed the clinical data of 110 patients(110 eyes)with diabetic macular edema treated in our hospital from January 2015 to January 2016, divided them into two groups according to the different treatment. Of these, treated 55 eyes with ranibizumab intravitreal injections(ranibizumab group)and the other with conbercept intravitreal injections(conbercept group), the injection came once a month for 8 continuous months with a 6-month follow-up. Compared the changes of visual acuity, macular thickness, postoperative comfort, clinical efficacy and complications between the two groups after treatment. <p>RESULTS: There was no significant difference in LogMAR visual acuity between the two groups before treatment(<i>P</i>>0.05). The visual acuity of the patients in the ranibizumab group and conbercept group were significantly improved after 1mo treatment, <i>F</i> were 42.06 and 64.02 respectively(<i>P</i><0.01), but there was no significant difference between the two groups after 1mo treatment(<i>P</i>>0.05). The visual acuity of the conbercept group was significantly higher than that of the ranibizumab group after 3 and 6mo treatment(<i>P</i><0.05). There was no significant difference in macular thickness between the two groups before treatment(<i>P</i>>0.05), the thickness of the macular fovea in the ranibizumab group and conbercept group was lower than that before treatment, there were statistically significant differences(<i>P</i><0.01); the decline range of conbercept group were more than those of the ranibizumab group after 3 and 6mo(<i>P</i><0.05). Patients comfort of the two groups improved with the passage of time after surgery, and there was no significant difference between the two groups(<i>P</i>>0.05), there were no significant differences in the total effective rate and complication of the ranibizumab group(87.3%, 1.8%)and the conbercept group(85.5%, 3.6%)(<i>P</i>>0.05). <p>CONCLUSION: In the treatment of diabetic macular edema, the early vision of patients with diabetic macular edema increases significantly, and the macular thickness decreases significantly. Conbercept works better and has a longer lasting effect after 3 and 6mo treatment, and conbercept is more economical.